Stay updated on Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study record for pembrolizumab combined with doxorubicin in advanced endometrial cancer is displayed, including its eligibility criteria, treatment plan, outcomes, study locations, and record dates.SummaryDifference45%

- Check17 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1. The page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision number changed from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study record content. This indicates an access restriction or server-side issue preventing viewing the NCT03276013 details.SummaryDifference17%

Stay in the know with updates to Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Doxorubicin in Endometrial Cancer Clinical Trial page.